An expert from Pharmatech Associates offers a glimpse into the evolution of CM and previews a lively discussion during the upcoming CPhI North America event.
A leader from the organizer of the pharmaceutical event discusses what’s in store for the upcoming conference, and for the drug development industry itself.
CPhI North America 2022 host city Philadelphia is set to become one of the world’s biggest cell and gene therapy manufacturing hubs. But it’s just one of many centers of innovation that are helping drive the US pharma and biopharma industry.
CDMO Piramal Pharma Solutions will expand capabilities of its Antibody-Drug Conjugate (ADC) facility in Grangemouth, Scotland; and invest in new Active Pharmaceutical Ingredient (API) infrastructure at its Morpeth, England facility.
The company will increase its production capacity for media, buffers, and other process liquids to meet the surge in demand that occurred alongside the pandemic.
A leader from Medicines for Europe will share with CPhI Worldwide attendees a look at medicine production and offer solutions for elevating the industry.
The global pharmaceutical industry event is returning to the real world November 9-11 this year, with online content for professionals opting not to travel.
The success of mRNA vaccine technology could be one of the new opportunities for US pharmaceutical manufacturing looking forward, with pandemic investments helping turbocharge the sector.
The pharma ingredients provider discusses new products, supply-chain obstacles, and what the future of the industry might hold, ahead of the online event.
Contract packaging provider Reed-Lane adds dedicated room for vial and ampule kitting to its cold chain capabilities to limit intra-facility travel and product excursion as a means of security.
Compared to June 2018, the biomedical manufacturing output in Singapore city rises by 5% this month, concurrently boosting the country’s overall pharmaceuticals output growth.
Bayer recalls vials of an antihemophilic treatment after the discovery that nearly 1,000 were mislabeled with a therapy indicated for an adult patient population.
CGT Catapult reports that employment has increased substantially, and production capacity has grown by 60% in the UK cell and gene therapy manufacturing industry.
Catalent Biologics works with Novartis to develop and manufacture its SMA gene therapy treatment and provide manufacturing capacity, as the treatment enters the market.
Paragon and Passage Bio enter a collaboration agreement to develop a dedicated manufacturing suite at the former’s Maryland facility, as the latter’s gene therapy candidates enter the clinic.
After a grant from the Bill & Melinda Gates Foundation, Univercells will adapt its low-footprint, cabinet-contained vaccine production line to create affordable measles and rubella vaccinations.
As the US faces a measles outbreak, and bills removing rights to exempt from vaccination are debated, vaccine manufacturers stress the need to educate the public.
WuXi Biologics expands its biologics conjugation solution center to include space for commercial manufacturing of antibody-drug conjugates for the biopharma industry.
Servier to work with Yposeski for the production of lentiviral vectors, as the former works to develop allogenic CAR-T cell technology for hematological therapies.
Thermo Fisher and Scinogy partner to improve scalability and cost-effectiveness of cell and gene therapy manufacture through the addition of the former’s centrifuge.
The private equity firm Ampersand Capital has acquired Vibalogics with plans to increase development and manufacturing capabilities for complex viral products.
GSK is investing in ‘significant’ capacity expansion to support production of its shingles vaccine, which has been approved in China after clinical trials demonstrated 90% efficacy.
Genentech will collaborate with biopharma company Parvus to manufacture and commercialize Navacim therapeutics for the treatment of autoimmune disease.
Lonza will provide manufacturing for Alector’s Phase I drug candidates for neurodegenerative diseases from its Switzerland site, which is expected to be operational by mid-2020.
Bluebird bio opens its first wholly owned manufacturing facility to produce lentiviral vectors for the company’s investigational gene and cell therapies.
GE Healthcare partners for digital data exchange collaboration program with Amgen to advance understanding of biomanufacturing process on raw material variability.
The global cell line development market grows steadily with a predicted revenue of $7.5bn by 2024, each component of the market to see CAGR between 10-15%.
ICT is developing upon CAR-T cell technology to enable T-cells to persist against cancer’s attempt to program death into a patient’s defensive T-cells, which could potentially treat solid tumors.
Fujifilm Diosynth announces the inception of its FDB center of excellence in bioprocessing 2.0 to extend its bioprocessing innovations with a network of researchers.
